rs11590235 — SKI
TGF-beta signaling regulator variant identified as the top shared locus between migraine and type 2 diabetes
Details
- Gene
- SKI
- Chromosome
- 1
- Risk allele
- T
- Consequence
- Regulatory
- Inheritance
- Additive
- Clinical
- Risk Factor
- Evidence
- Moderate
- Chip coverage
- v3 v4 v5
Population Frequency
Ancestry Frequencies
Related SNPs
Category
Heart & InflammationSee your personal result for SKI
Upload your DNA data to find out which genotype you carry and what it means for you.
Upload your DNA dataWorks with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.
The TGF-Beta Gatekeeper Linking Inflammation, Migraine, and Metabolic Disease
The SKI proto-oncogene encodes a transcriptional co-repressor that acts
as one of the most potent negative regulators of the
TGF-beta signaling pathway11 TGF-beta signaling pathway
TGF-beta (Transforming Growth Factor-beta) controls cell proliferation, differentiation, apoptosis, and immune regulation throughout the body.
The rs11590235 variant, located within an intron of SKI on chromosome
1p36.33, achieved the highest statistical significance of any shared
locus between migraine and type 2 diabetes in a large cross-trait GWAS
meta-analysis (P = 3.11 x 10-12).
The Mechanism
SKI protein binds directly to SMAD proteins, which are the intracellular signal transducers of TGF-beta. By disrupting SMAD2/SMAD4 complexes and recruiting histone deacetylases (HDACs), SKI keeps TGF-beta target genes silenced under basal conditions. When TGF-beta signaling is activated (by injury, inflammation, or metabolic stress), SKI is degraded, allowing target gene expression. 22 SKI and the related protein SnoN constitute a small family of nuclear oncoproteins that modulate the cellular response to TGF-beta superfamily ligands
The rs11590235 T allele likely alters SKI expression or splicing efficiency, shifting the balance of TGF-beta pathway regulation. This has two key downstream consequences: (1) altered vascular smooth muscle cell function and endothelial inflammation relevant to migraine pathophysiology, and (2) impaired TGF-beta-mediated insulin signaling and pancreatic beta-cell regulation relevant to type 2 diabetes.
The Evidence
The cross-trait GWAS meta-analysis33 cross-trait GWAS meta-analysis
Siewert-Rocks et al. Genetic Overlap Analysis Identifies a Shared Etiology between Migraine and Headache with Type 2 Diabetes. Genes, 2022
identified rs11590235 at the SKI locus as the most significant of 23
novel shared loci between migraine and T2D, with concordant risk
effects (migraine OR 1.05, T2D OR 1.05 for the T allele). The
signal was robust with P = 3.11 x 10-12, far exceeding genome-wide
significance.
A complementary study44 complementary study
Islam et al. Cross-trait analyses identify shared genetics between migraine, headache, and glycemic traits. Hum Genet, 2023
confirmed the genetic correlation between migraine and type 2 diabetes
(rg = 0.06, P = 1.37 x 10-5) and identified pleiotropic regions
between migraine and fasting insulin, fasting glucose, and glycated
haemoglobin. Mendelian randomisation analyses suggested increased
fasting proinsulin levels may causally decrease the risk of headache.
The T allele is notably rare in East Asian (0.1%) and African (1.3%) populations but more common in South Asians (8.1%) and Europeans (6.0%), reflecting population-specific selection pressures on TGF-beta pathway regulation.
Practical Actions
The T allele at SKI shifts TGF-beta pathway balance, potentially increasing low-grade vascular inflammation. Carriers may benefit from targeted anti-inflammatory nutritional strategies and monitoring inflammatory and glycemic biomarkers to detect early metabolic changes.
Interactions
TGF-beta signaling intersects with insulin signaling at multiple nodes, including SMAD-mediated regulation of glucose transporter expression and pancreatic beta-cell function. Carriers who also have TCF7L2 risk alleles (rs7903146) may experience compounding effects on diabetes risk through independent but converging pathways.
Genotype Interpretations
What each possible genotype means for this variant:
Standard SKI-mediated TGF-beta pathway control
You carry two copies of the common C allele at this SKI locus. Your TGF-beta signaling pathway has normal regulation through the SKI co-repressor. About 91% of the global population shares this genotype. Your baseline vascular and inflammatory signaling through TGF-beta operates at standard levels.
One copy shifts TGF-beta regulation with shared migraine-metabolic risk
SKI is a key negative regulator of TGF-beta signaling. The T allele at rs11590235 was identified with the strongest cross-trait signal (P = 3.11 x 10-12) between migraine and type 2 diabetes, with concordant odds ratios of 1.05 for both conditions. TGF-beta signaling plays central roles in vascular smooth muscle function, endothelial integrity, and pancreatic beta-cell regulation. Altered SKI-mediated repression could shift the balance toward increased basal TGF-beta activity, promoting both low-grade vascular inflammation and subtle impairments in insulin signaling.
Two copies significantly shift TGF-beta signaling with elevated migraine-metabolic risk
Homozygous TT carriers at rs11590235 have the maximum genetic loading at the most significant shared migraine-T2D locus identified to date. SKI normally acts as a brake on TGF-beta signaling; with both copies of the T allele, this brake may function less efficiently, leading to increased baseline TGF-beta pathway activity. This affects vascular smooth muscle tone and endothelial function (relevant to migraine aura and headache) as well as pancreatic beta-cell responsiveness and insulin signaling (relevant to T2D). The rarity of this genotype means direct clinical data is limited, but the biological plausibility and the strength of the GWAS signal support proactive monitoring.
Key References
Siewert-Rocks et al. cross-trait GWAS identifying rs11590235 as the top shared locus between migraine and T2D (P = 3.11 x 10^-12)
Islam et al. cross-trait analyses identifying shared genetics between migraine, headache, and glycemic traits
Deheuninck and Bhatt review of Ski and SnoN as potent negative regulators of TGF-beta signaling
Colak and ten Dijke review of TGF-beta signaling in health, disease, and therapeutics including vascular and metabolic contexts